Axcelius I/II website screenshot

Axcelius I/II

Axcelius I/II is a biopharmaceutical company-creation vehicle backed by Canaan Partners, formed to found and incubate drug-development companies pursuing treatments for cancer, rare diseases, and neurodegenerative disorders. It is led by managing partner Dennis Podlesak and sponsored at Canaan by general partner Brent Ahrens, and operates from San Francisco, California, with an associated holding entity registered in Connecticut at Canaan's Westport office. Rather than operating as a product company, Axcelius assembles management teams and capital around licensed therapeutic assets and spins them out as standalone biopharma companies; Transposon Therapeutics, developing therapies for ALS and Alzheimer's disease, is its best-documented creation. As of this enrichment pass the vehicle remains in stealth mode with no public developer surface -- no product website beyond a holding page, no documentation, developer portal, SDKs, GitHub organization, or API of any kind.

Axcelius I/II is profiled on the APIs.io network. Tagged areas include Company, Venture Capital, Company Creation, Biopharmaceutical, and Life Sciences.

🌐 Visit website 📡 Source on GitHub
7.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyVenture CapitalCompany CreationBiopharmaceuticalLife SciencesDrug DiscoveryOncologyRare DiseaseNeurodegenerative DiseaseStealth

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 7.7/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/axcelius-i-ii: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Axcelius I Ii Domain Security

TLSv1.2

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 2

The organization behind the API

Website
Website
 InvestorProfile
InvestorProfile

Source (apis.yml)

apis.yml Raw ↑ 
aid: axcelius-i-ii
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/axcelius-i-ii.png
name: Axcelius I/II
description: Axcelius I/II is a biopharmaceutical company-creation vehicle backed by Canaan Partners, formed to found and
  incubate drug-development companies pursuing treatments for cancer, rare diseases, and neurodegenerative disorders. It is
  led by managing partner Dennis Podlesak and sponsored at Canaan by general partner Brent Ahrens, and operates from San Francisco,
  California, with an associated holding entity registered in Connecticut at Canaan's Westport office. Rather than operating
  as a product company, Axcelius assembles management teams and capital around licensed therapeutic assets and spins them
  out as standalone biopharma companies; Transposon Therapeutics, developing therapies for ALS and Alzheimer's disease, is
  its best-documented creation. As of this enrichment pass the vehicle remains in stealth mode with no public developer surface
  -- no product website beyond a holding page, no documentation, developer portal, SDKs, GitHub organization, or API of any
  kind.
url: https://raw.githubusercontent.com/api-evangelist/axcelius-i-ii/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: stealth-company-creation-vehicle-no-public-api-surface
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Venture Capital
- Company Creation
- Biopharmaceutical
- Life Sciences
- Drug Discovery
- Oncology
- Rare Disease
- Neurodegenerative Disease
- Stealth
apis: []
common:
- type: DomainSecurity
  url: security/axcelius-i-ii-domain-security.yml
- type: Website
  url: https://axcelius.com/
  x-verification: Unconfirmed attribution. axcelius.com serves only a 386-byte "AXCELIUS" holding page (HTTP 200, GoDaddy
    hosting). Registered 2019-07-31, three weeks before Axcelius Holding Company, LLC was registered in Connecticut (2019-08-20)
    at Canaan Partners' Westport office; WHOIS registrant is privacy protected. Timing and naming corroborate but do not prove
    the association.
- type: InvestorProfile
  url: https://www.canaan.com/companies/axcelius-i-ii
x-enrichment:
  date: '2026-07-20'
  status: minimal
  artifacts_added: 2
  pass: local-v1
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io